Revium Rx Reports Q1 2026 Financial Results with $725K Net Loss and Increased R&D Expenses

Revium Rx, a biopharmaceutical company focused on developing innovative nano-medicines, reported its financial results for the first quarter of 2026, revealing a net loss of $725,634, a decrease of 14.3% from the $634,000 loss recorded in the same period of 2025. The company’s operating loss for the quarter was $739,737, slightly up from $737,000 year-over-year. Revium has not generated any revenue from product sales to date, and its accumulated deficit has reached $25.7 million as of March 31, 2026.

The company’s total operating expenses for the first quarter of 2026 amounted to $739,737, with research and development expenses significantly increasing to $473,218, up 116.9% from $218,000 in the prior year. This rise is attributed to the initiation of a development and manufacturing services agreement for its Nano-Mupirocin program, which is advancing toward clinical trials. In contrast, general and administrative expenses decreased by 48.7% to $266,519, primarily due to lower share-based payment expenses and a shift in executive focus towards research and development.

Revium Rx has undergone significant strategic changes, including the acquisition of LipoVation Ltd., which became a wholly owned subsidiary in July 2024. This acquisition has shifted the company’s focus towards developing lipid-based therapies for infectious diseases and cancer. The company is currently advancing its Nano-Mupirocin program, having received authorization from the Israeli Ministry of Health to initiate Phase 1 clinical trials. However, progress on other programs, such as Nano-Candesartan, has been delayed due to unresolved contractual matters.

As of March 31, 2026, Revium Rx reported total assets of $7.8 million, down from $8.3 million at the end of 2025. The company’s cash and cash equivalents decreased to $920,000 from $1.7 million, reflecting ongoing operational expenditures. Revium’s employee headcount remains stable, with no significant changes reported. The company continues to seek additional capital to fund its research and development activities, with management expressing concerns about its ability to continue as a going concern without securing further investments.

Looking ahead, Revium Rx aims to complete stability studies for its Nano-Mupirocin program and initiate clinical trials as authorized. The company is also focused on resolving outstanding issues affecting its other development programs. However, management cautions that the timing and success of these initiatives are subject to significant risks, including regulatory reviews and the availability of capital, which may impact future operations and development timelines.